Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, 2-arm, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of BNC210 for the Acute, As-needed Treatment of Anxiety in Adults With Social Anxiety Disorder

Next Previous
Trial Profile

A Phase 3, Randomized, Double-blind, 2-arm, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of BNC210 for the Acute, As-needed Treatment of Anxiety in Adults With Social Anxiety Disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BNC 210 (Primary)
  • Indications Anxiety disorders; Social phobia
  • Focus Registrational; Therapeutic Use
  • Acronyms AFFRIM-1
  • Sponsors Bionomics

Most Recent Events

  • 24 Oct 2025 Status changed from active, no longer recruiting to completed.
  • 20 Oct 2025 According to Neuphoria Therapeutics media release, based on the results from the AFFIRM-1 trial, Neuphoria will discontinue further development of its SAD program.
  • 20 Oct 2025 Results presented in the Neuphoria Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top